This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBecton Dickinson（BOX）株式概要ベクトン・ディッキンソン アンド カンパニーは、世界中の医療機関、医師、ライフサイエンス研究者、臨床検査室、製薬業界、一般消費者向けに医療用品、機器、検査機器、診断用製品を開発、製造、販売している。 詳細BOX ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長2/6過去の実績1/6財務の健全性4/6配当金5/6報酬当社が推定した公正価値より44.4%で取引されている 収益は年間18.52%増加すると予測されています 1.63%の安定した配当金を支払う リスク分析財務結果に影響を与える大きな一時的項目 多額の負債を抱えている 過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見るBOX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW502,015 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG502,015 investors already sharing narrativesYour Fair Value€Current Price€218.3510.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture026b2016201920222025202620282031Revenue US$25.8bEarnings US$1.9bAdvancedSet Fair ValueView all narrativesBecton, Dickinson and Company 競合他社Siemens HealthineersSymbol: XTRA:SHLMarket cap: €39.3bMedtronicSymbol: NYSE:MDTMarket cap: US$106.3bGE HealthCare TechnologiesSymbol: NasdaqGS:GEHCMarket cap: US$29.5bBoston ScientificSymbol: NYSE:BSXMarket cap: US$66.3b価格と性能株価の高値、安値、推移の概要Becton Dickinson過去の株価現在の株価US$218.3552週高値US$052週安値US$0ベータ0.441ヶ月の変化4.98%3ヶ月変化0.37%1年変化-14.62%3年間の変化n/a5年間の変化n/aIPOからの変化1.83%最新ニュースReported Earnings • Aug 02Third quarter 2024 earnings released: EPS: US$1.68 (vs US$1.37 in 3Q 2023)Third quarter 2024 results: EPS: US$1.68 (up from US$1.37 in 3Q 2023). Revenue: US$4.99b (up 2.3% from 3Q 2023). Net income: US$487.0m (up 24% from 3Q 2023). Profit margin: 9.8% (up from 8.0% in 3Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Europe.お知らせ • Aug 01Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024Becton, Dickinson and Company updated earnings guidance for the year 2024. For the year, the company expects GAAP Revenues in the range of $20.1 billion compared to the previous guidance of $20.1 to $20.3 billion provided earlier and expects GAAP Revenue Growth of 3.7%. Organic Revenue Growth of 5.0% to 5.25% compared to the previous guidance of 5.5% to 6.25% provided earlier.お知らせ • Jul 24Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024The Board of Directors of BD (Becton, Dickinson and Company) announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share.お知らせ • Jul 04Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024Becton, Dickinson and Company announced that they will report Q3, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 01, 2024お知らせ • Jun 26BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research ToolBD (Becton, Dickinson and Company) announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases. Researchers worldwide are currently using innovative approaches to study multiple aspects of health and disease at a single-cell level. In the ever-evolving field of biological research, the newly launched BD Rhapsody Single Cell ATAC-Seq (assay for transposase-accessible chromatin using next-generation sequencing) Assay enables scientists to perform single-cell analysis of the epigenome – the set of chemical marks, or epigenetic changes, on the DNA in a single cell that holds critical clues about mechanisms of disease. Adding an epigenomic layer-view will play a crucial role in helping researchers track and understand how environmental factors impact the DNA and corresponding cell function. By gaining such knowledge about DNA, scientists can deepen their understanding of how diseases progress and apply those learnings to develop effective therapies. Commercially available globally June 26, 2024, the BD Rhapsody ATAC-Seq Assay, BD Rhapsody TCR/BCR Next Multiomic Assay and BD Rhapsody Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell research. The BD single-cell multiomics portfolio is available for purchase from BD representatives, or in some regions, through its ecommerce portal.お知らせ • Jun 05Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion on June 3, 2024. BD expects to fund the all-cash transaction with approximately $1 billion of cash and $3.2 billion of new debt. Upon closing, Critical Care will operate as a separate business unit within BD’s Medical segment to align with its smart connected care approach, and it will maintain its presence in Irvine, Calif. Katie Szyman, who has served as corporate vice president of Critical Care since 2015, will lead the new business unit within BD, reporting to Mike Garrison, executive vice president and president of the BD Medical segment. The transaction is subject to customary regulatory reviews, the receipt of required antitrust and foreign investment approvals and closing conditions. The transaction is expected to close before the end of the 2024. At closing, BD is expected to have net leverage of approximately 3x and expects to de-lever to its 2.5x long-term net leverage target within 12 to 18 months of closing, primarily by deploying its free cash flows to debt repayment. The transaction meets all of BD’s rigorous investment criteria on growth, profitability and returns. It is expected to be immediately accretive to all key financial measures, including BD’s revenue growth, adjusted gross and operating margins, and adjusted earnings per share. Critical Care’s long-term financial profile is also expected to deliver durable revenue growth of approximately 6% to 7%, with year-one adjusted gross margin of at least 60% and adjusted operating margins of at least 25% that increase over time. Consistent with the company’s BD 2025 strategy, growth-enhancing and value-creating tuck-in M&A continues to be a key part of BD’s targeted financial profile. Perella Weinberg Partners and Citi acted as financial advisers, and Ropes & Gray, LLP acted as legal counsel to BD. Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC acted as financial advisors, and Skadden Arps acted as legal counsel to Edwards.最新情報をもっと見るRecent updatesReported Earnings • Aug 02Third quarter 2024 earnings released: EPS: US$1.68 (vs US$1.37 in 3Q 2023)Third quarter 2024 results: EPS: US$1.68 (up from US$1.37 in 3Q 2023). Revenue: US$4.99b (up 2.3% from 3Q 2023). Net income: US$487.0m (up 24% from 3Q 2023). Profit margin: 9.8% (up from 8.0% in 3Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Europe.お知らせ • Aug 01Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024Becton, Dickinson and Company updated earnings guidance for the year 2024. For the year, the company expects GAAP Revenues in the range of $20.1 billion compared to the previous guidance of $20.1 to $20.3 billion provided earlier and expects GAAP Revenue Growth of 3.7%. Organic Revenue Growth of 5.0% to 5.25% compared to the previous guidance of 5.5% to 6.25% provided earlier.お知らせ • Jul 24Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024The Board of Directors of BD (Becton, Dickinson and Company) announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share.お知らせ • Jul 04Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024Becton, Dickinson and Company announced that they will report Q3, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 01, 2024お知らせ • Jun 26BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research ToolBD (Becton, Dickinson and Company) announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases. Researchers worldwide are currently using innovative approaches to study multiple aspects of health and disease at a single-cell level. In the ever-evolving field of biological research, the newly launched BD Rhapsody Single Cell ATAC-Seq (assay for transposase-accessible chromatin using next-generation sequencing) Assay enables scientists to perform single-cell analysis of the epigenome – the set of chemical marks, or epigenetic changes, on the DNA in a single cell that holds critical clues about mechanisms of disease. Adding an epigenomic layer-view will play a crucial role in helping researchers track and understand how environmental factors impact the DNA and corresponding cell function. By gaining such knowledge about DNA, scientists can deepen their understanding of how diseases progress and apply those learnings to develop effective therapies. Commercially available globally June 26, 2024, the BD Rhapsody ATAC-Seq Assay, BD Rhapsody TCR/BCR Next Multiomic Assay and BD Rhapsody Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell research. The BD single-cell multiomics portfolio is available for purchase from BD representatives, or in some regions, through its ecommerce portal.お知らせ • Jun 05Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion on June 3, 2024. BD expects to fund the all-cash transaction with approximately $1 billion of cash and $3.2 billion of new debt. Upon closing, Critical Care will operate as a separate business unit within BD’s Medical segment to align with its smart connected care approach, and it will maintain its presence in Irvine, Calif. Katie Szyman, who has served as corporate vice president of Critical Care since 2015, will lead the new business unit within BD, reporting to Mike Garrison, executive vice president and president of the BD Medical segment. The transaction is subject to customary regulatory reviews, the receipt of required antitrust and foreign investment approvals and closing conditions. The transaction is expected to close before the end of the 2024. At closing, BD is expected to have net leverage of approximately 3x and expects to de-lever to its 2.5x long-term net leverage target within 12 to 18 months of closing, primarily by deploying its free cash flows to debt repayment. The transaction meets all of BD’s rigorous investment criteria on growth, profitability and returns. It is expected to be immediately accretive to all key financial measures, including BD’s revenue growth, adjusted gross and operating margins, and adjusted earnings per share. Critical Care’s long-term financial profile is also expected to deliver durable revenue growth of approximately 6% to 7%, with year-one adjusted gross margin of at least 60% and adjusted operating margins of at least 25% that increase over time. Consistent with the company’s BD 2025 strategy, growth-enhancing and value-creating tuck-in M&A continues to be a key part of BD’s targeted financial profile. Perella Weinberg Partners and Citi acted as financial advisers, and Ropes & Gray, LLP acted as legal counsel to BD. Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC acted as financial advisors, and Skadden Arps acted as legal counsel to Edwards.お知らせ • May 03Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024Becton, Dickinson and Company revised earnings guidance for the fiscal year 2024. For the year, company expects revenues to be in the range of approximately $20.1 billion to $20.3 billion compared to previous guidance of $20.2 billion to $20.4 billion. The company now expects organic revenue growth to be 5.5% to 6.25% compared to previous guidance of 5.5% to 6.25%.Reported Earnings • May 02Second quarter 2024 earnings released: EPS: US$1.86 (vs US$1.54 in 2Q 2023)Second quarter 2024 results: EPS: US$1.86 (up from US$1.54 in 2Q 2023). Revenue: US$5.05b (up 4.6% from 2Q 2023). Net income: US$537.0m (up 23% from 2Q 2023). Profit margin: 11% (up from 9.1% in 2Q 2023). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe.お知らせ • May 01Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024The Board of Directors of BD (Becton, Dickinson and Company) announced it has declared a quarterly dividend of $0.95 per common share, payable on June 28, 2024 to holders of record on June 10, 2024. The indicated annual dividend rate is $3.80 per share.お知らせ • Apr 27Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC recently.お知らせ • Apr 05+ 1 more updateBecton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024Becton, Dickinson and Company announced that they will report Q2, 2024 results at 6:30 AM, US Eastern Standard Time on May 02, 2024お知らせ • Mar 06Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial DiseaseBecton, Dickinson and Company announced the enrollment of the first patient in the investigational device exemption (IDE) study, AGILITY, which will assess the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Peripheral Arterial Disease (PAD). The investigational Vascular Covered Stent is a self-expanding, low profile, polytetrafluoroethylene encapsulated nitinol implant. It is deployed from a delivery system that provides controlled stent release. According to BD, the global, prospective, multi-center, single-arm, non-randomized AGILITY clinical study will include 315 patients at up to 40 clinical study sites across the United States, Europe, Australia and New Zealand. Follow-up for all treated patients will be performed at various points after treatment starting at one month and ending at 36 months. PAD affects more than 18 million Americans and more than 236 million people worldwide. It is a potentially debilitating disease that can lead to increased risk of cardiovascular complications and limb amputation. A healthy diet, exercise and cessation of smoking can help mitigate the development of PAD, which includes the formation of atherosclerosis and blood clots in arteries in the legs. Minimally invasive techniques using devices such as angioplasty balloons, drug-coated balloons, atherectomy and covered stents can be used to increase blood flow through the diseased areas. The first patient in the AGILITY study was enrolled at Trinity Medical Center in Bettendorf, Iowa by Dr. Nicolas Shammas, Interventional Cardiologist, Cardiovascular Medicine, PLLC.お知らせ • Feb 29Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024BD (Becton, Dickinson and Company) announced that Dave Hickey has informed the company of his intent to retire from BD, effective July 1, 2024. Hickey is currently executive vice president and president of the Life Sciences segment for BD, a position he has held since January 2021. Prior to his current role, Hickey was president of Integrated Diagnostic Solutions from 2019 to 2021, and president of Diagnostic Systems prior to that. Before joining BD in 2014, Hickey served in a range of executive leadership positions at Siemens Healthcare. BD intends to name a successor to Hickey prior to his retirement date.Reported Earnings • Feb 01First quarter 2024 earnings released: EPS: US$0.97 (vs US$1.71 in 1Q 2023)First quarter 2024 results: EPS: US$0.97 (down from US$1.71 in 1Q 2023). Revenue: US$4.71b (up 2.6% from 1Q 2023). Net income: US$281.0m (down 42% from 1Q 2023). Profit margin: 6.0% (down from 11% in 1Q 2023). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Europe.お知らせ • Feb 01Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024Becton, Dickinson and Company raised earnings guidance for the fiscal year of 2024. For the year, company expects revenues to be in the range of approximately $20.2 billion to $20.4 billion compared to $20.1 billion to $20.3 billion previously and Organic revenue growth is now expected to be 5.5% to 6.25% compared to 5.25% to 6.25% previously.お知らせ • Jan 24Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024The Board of Directors of Becton, Dickinson and Company announced it has declared a quarterly dividend of $0.95 per common share, payable on March 29, 2024 to holders of record on March 8, 2024. The indicated annual dividend rate is $3.80 per share.お知らせ • Jan 05Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024Becton, Dickinson and Company announced that they will report Q1, 2024 results at 6:30 AM, US Eastern Standard Time on Feb 01, 2024お知らせ • Dec 16Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024, at 13:00 US Eastern Standard Time.お知らせ • Dec 08BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection DeviceBD announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests. The BD MiniDraw™ Capillary Blood Collection System is less invasive than a traditional venous blood draw by using capillary blood collected from a patient's finger by a trained healthcare worker, without the need for a phlebotomist to collect blood from a vein. The innovative design provides a sample that produces lab-quality blood test results from a fraction of the volume of traditional venous collections. It is less invasive than traditional venous blood collection methods and more convenient for the patient by expanding access to blood collection to new locations, including retail pharmacies. The device may provide a better patient experience and has the potential to transform diagnostic testing. The 510(k) clearances include low-volume blood collection for a lipid panel, selected chemistry tests, and hemoglobin and hematocrit (H&H) testing. These tests are among the most commonly ordered lab tests and can be used to diagnose and monitor a variety of chronic conditions from hypertension to high cholesterol. BD plans to expand blood tests enabled by BD MiniDraw™ Collection System in the future.Traditionally when a patient requires "blood work," a doctor orders the test, and an appointment is made at a laboratory service center where a nurse or phlebotomist draws tubes of blood from the patient's vein. The BD MiniDraw™ Collection System has the potential to transform this experience by expanding blood testing to new, more convenient settings, which can benefit patients, health care providers and collection sites. For patients, capillary collection with the BD MiniDraw™ Collection System provides the convenience of having blood drawn somewhere they already frequent, like a retail pharmacy or grocery store, which may have longer hours of operation and be closer to where they live or work. For these non-traditional collection sites, it enables expansion beyond existing health and wellness programs like administering vaccinations and can generate additional store traffic. For health care providers, capillary blood collection could be offered at a physician's office without the need for a phlebotomist. Making blood collection easier and less invasive may improve patient adherence to blood testing, for example, as part of annual wellness checks, which could lead to earlier diagnosis and better monitoring of chronic conditions. In May 2022, BD and Babson Diagnostics announced an expansion of their original strategic partnership agreement, announced in 2020, to advance development of the Babson BetterWay™ blood testing ecosystem, which includes the BD MiniDraw™ Collection System and Babson's proprietary automated sample-handling and analytical technologies. These were designed to work together to enable blood testing that requires only a fraction of the sample volume of traditional venipuncture methods without sacrificing quality or accuracy.お知らせ • Nov 30BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician EfficiencyBD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices. The SiteRite™? 9 Ultrasound System is an all-in-one system designed with a user-friendly experience on an updated 15.6-inch touch screen with enhanced image quality that provides catheter placement tools and technologies to support clinicians during the vascular access device insertion process. The system includes integrated visualization tools such as the Cue™? Needle Tracking System to provide nurses with continuous and real-time needle tracking, and the Sherlock 3CG+™? Tip Confirmation System to ensure proper catheter tip navigation and location. SiteRite™? 9 also features smart, connected technology such as vessel assessment tools that automatically detect the vessel, then pair with vessel measurement tools to help clinicians select the appropriate catheter, so they can make an informed decision every time. Additional system capabilities include patient data look up with information capture, auto-filling capabilities and records transfer to help support clinician workflow.お知らせ • Nov 23Becton, Dickinson and Company Announces Executive ChangesBecton, Dickinson and Company (BDX) named Ronald Silverman as executive vice president and chief medical officer, effective Dec. 4, 2023. Silverman succeeds William Sigmund, who had announced his wish to retire in June this year. Silverman was chief medical officer at 3M Health Care before joining BD.New Risk • Nov 14New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 30% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results.Reported Earnings • Nov 14Full year 2023 earnings released: EPS: US$5.14 (vs US$5.42 in FY 2022)Full year 2023 results: EPS: US$5.14 (down from US$5.42 in FY 2022). Revenue: US$19.4b (up 2.7% from FY 2022). Net income: US$1.47b (down 4.9% from FY 2022). Profit margin: 7.6% (down from 8.2% in FY 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Europe.お知らせ • Nov 12Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023The Board of Directors of Becton, Dickinson and Company has declared a quarterly dividend of $0.95 per common share, an increase of 4.4% from the previous quarter. The dividend will be payable on December 29, 2023 to holders of record on December 8, 2023. The indicated annual dividend rate for fiscal year 2024 is $3.80 per share.お知らせ • Nov 10Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024Becton, Dickinson and Company provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of approximately $20.1 billion to $20.3 billion. Organic revenue growth is expected to be 5.25% to 6.25% including a headwind of over 25 basis points from the expected decline in COVID-only diagnostic testing. Total currency-neutral revenue growth is expected to be 4.5% to 5.5%. The company expects fiscal year 2024 adjusted diluted EPS to be $12.70 to $13.00, which represents growth of approximately 4% to 6.5%.Buying Opportunity • Nov 09Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 19%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.お知らせ • Nov 03Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw TechnologyBecton, Dickinson and Company launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company's vision of a "One-Stick Hospital Stay." With 510(k) clearance from the U.S. Food and Drug Administration (FDA), the new PIVO Pro Needle-free Blood Collection Device features design improvements to achieve the first and only compatibility with integrated and long peripheral IV catheters, including the new Nexiva Closed IV Catheter System with NearPort IV Access. This expands on current PIVO compatibility with traditional short peripheral IV catheters available since 2017. The new solution combines the clinical benefits shown for the integrated closed Nexiva Catheter System, including longer dwell times and reduced catheter complications, with the ability to draw high-quality blood samples directly from a patient's peripheral IV line with PIVO Pro, reducing the need for additional needlesticks. With needle phobia experienced by more than 60 percent of the adult population, this solution helps improve the patient experience by alleviating fear and anxiety associated with repetitive needlesticks. This new solution helps to reduce unnecessary and repeat needlesticks in the hospital while elevating clinical outcomes, improving workflow and creating a better experience for clinicians and patients." Peripheral IV insertion and blood collection are two of the most common in-patient procedures in hospitals touching almost every patient daily. These invasive procedures are associated with a variety of complications such as poor first-stick insertion success, frequent catheter failures and poor sample quality that can extend hospital stays, increase cost and create a dissatisfying experience. PIVO Pro combined with Nexiva with NearPort IV Access is designed to access optimal blood draw conditions and help improve clinician efficiency and patient experience. The innovative line draw solution has been shown to help optimize IV performance, reduce sample errors that can result in redraws and delays in patient care while reducing complications that lead to unnecessary procedures and IV replacements. By removing the needle from blood draws and reducing IV replacements, it may reduce the risk of needlestick injury and blood exposure for clinicians while preserving a patient's vessel health.(7,9,10) As the global leader in vascular access solutions, BD is committed to advancing the standard of care for IV therapy and blood draws for patients and health care providers. The latest innovation in the BD Peripheral Line Draw Solution further drives the BD "One-Stick Hospital Stay" vision across each of its three pillars _ including (1) helping to reduce unnecessary needlesticks by choosing the right vascular access device and placing it successfully the first time; (2) using one IV line as a single access point for required therapies and blood draws; and (3) optimal maintenance of the IV line to help reduce the risk of complications so it does not have to be replaced and lasts throughout a patient's hospital stay. Compared to open catheter system- Clinical studies were done on previous generations of the PIVO Blood Collection Device and Nexiva Catheter System. PIVO Pro and Nexiva with NearPort IV Access are the next generations of their respective product families.お知らせ • Oct 18BD Names Greg Rodetis as Senior Vice President of Investor RelationsBD (Becton, Dickinson and Company) announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately. In this expanded role, Greg will continue as company treasurer and also lead all aspects of communicating progress of BD's strategy to investors and the financial community, including the company's initiatives that drive shareholder value. Rodetis will continue to report to Chris DelOrefice, executive vice president and chief financial officer for BD. Rodetis joined BD in 2016 as vice president and assistant treasurer, capital markets. In his current role as treasurer, Rodetis is responsible for leadership and oversight of the company's Treasury function as a strategic partner in supporting business performance, earnings growth and shareholder return. Prior to BD, Greg was with Terex Corporation as the assistant treasurer and prior to this he held roles of progressive responsibility with PepsiCo Inc., and General Electric Company. Rodetis holds a Bachelor of Science in Finance from Boston College and is a CFA® Charterholder.お知らせ • Oct 13Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023Becton, Dickinson and Company announced that they will report Q4, 2023 results at 6:30 AM, US Eastern Standard Time on Nov 09, 2023Buying Opportunity • Sep 29Now 21% undervaluedOver the last 90 days, the stock is up 1.7%. The fair value is estimated to be €309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 19%. For the next 3 years, revenue is forecast to grow by 5.0% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.New Risk • Aug 04New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results.お知らせ • Aug 04+ 1 more updateBecton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the full fiscal year 2023. For the period, Company now expects revenues to be approximately $19.3 billion compared to $19.2 billion to $19.3 billion previously announced. Revenue guidance now assumes base business currency-neutral revenue growth of 6.8% to 7.1% before the impact of the Surgical Instrumentation platform divestiture. This reflects an increase of 25 basis points at the mid-point to 7.0%, driven by strong third quarter performance. Base organic revenue growth is now expected to be 5.5% to 5.8%, compared to 5.25% to 5.75% previously announced, and continues to reflect fourth quarter organic revenue growth of about 6%.Reported Earnings • Aug 03Third quarter 2023 earnings released: EPS: US$1.37 (vs US$1.29 in 3Q 2022)Third quarter 2023 results: EPS: US$1.37 (up from US$1.29 in 3Q 2022). Revenue: US$4.88b (up 5.1% from 3Q 2022). Net income: US$392.0m (up 6.8% from 3Q 2022). Profit margin: 8.0% (up from 7.9% in 3Q 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Europe.お知らせ • Jul 25Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the BoardOn July 24, 2023, Dr. Joanne Waldstreicher was elected to the Board of Directors of Becton, Dickinson and Company (BD"). Upon joining BD's Board of Directors, Dr. Waldstreicher will serve as a member of both the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board. BD's Board of Directors has determined that Dr. Waldstreicher is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD's Statement of Corporate Governance Principles. Information regarding the compensation of the non-management members of BD's Board of Directors is included under the caption Non-Management Director Compensation" in BD's proxy statement relating to its 2023 Annual Meeting of Shareholders.お知らせ • Jul 23Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion SystemBD (Becton, Dickinson and Company) announced that the updated BD Alaris Infusion System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the United States. This clearance covers updated hardware features for Point-of-Care Unit (PCU), large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring and auto-identification modules. It also covers a new BD Alaris Infusion System software version with enhanced cybersecurity, along with interoperability features that enable smart, connected care with the most widely used electronic medical record (EMR) systems. Extending BD's Decades-Long Legacy of Leadership in Infusion Innovation: Today's clearance further enhances BD leadership in the infusion pump market. The updated BD Alaris Infusion system will help empower hospitals and health systems to optimize their workflows and deliver a higher standard of care, which has never been more important than in today's health care environment of staffing shortages and resource constraints. The BD Alaris Infusion System is the only system with a centralized user interface for up to four modules for all major types of infusions, including large volume pumps, syringe pump, and PCA therapy with optional respiratory monitoring. Having one, comprehensive infusion system enables hospitals and health systems to easily scale their infusion needs across an entire integrated delivery network and provide interoperability with EMR interoperability. With a common Point-of-Care Unit, one interface controls all modules, which is different from other pumps on the market that have non-modular architecture. The "one system" approach offers ease, simplicity and scalability. The BD Alaris infusion System also has the breadth of customers, the number of nurses trained on its use and the broadest experience and number of customers with EMR interoperability. Without this type of digital connectivity, clinicians are often required to navigate time-consuming processes, taking multiple steps to manually program infusions. The BD Alaris Inf Fusion System can also feed data to the BD HealthSight™? platform for enterprise medication management, which is a unique combination of connective technologies, analytics and expert services that turn information into insights among caregivers and create seamless visibility across BD medication management solutions. With this platform, health systems can view infusion status in real-time as well as access an intuitive knowledge portal with actionable information related to clinician trends and drug and fluid libraries.お知らせ • Jul 07Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023Becton, Dickinson and Company announced that they will report Q3, 2023 results at 9:30 AM, US Eastern Standard Time on Aug 03, 2023お知らせ • Jun 21STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.STERIS Corporation entered into an agreement to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million On June 15, 2023. The purchase price is subject to customary adjustments. STERIS Corporation will acquire the BD platform assets relating to surgical instrumentation, laparoscopic instrumentation and sterilization containers, including the V. Mueller, Snowden Pencer and Genesis branded products. The purchase price for the Transaction is $540 million in cash, subject to customary adjustments. STERIS is not assuming any debt and intends to fund the Transaction through a combination of debt and cash on hand. STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill, with a present value of approximately $60 million. The Purchase Agreement also imposes customary confidentiality, non-solicitation and non-compete obligations upon the BD. The Purchase Agreement provides STERIS and the BD with certain termination rights. The completion of the Transaction is subject to the satisfaction or waiver of a number of customary conditions, including receipt of requisite Hart-Scott-Rodino Act approvals and Federal Trade Commission (FTC) regulatory approval. The divestiture will include V. Mueller™, Snowden-Pencer™ and Genesis™ branded products and three manufacturing facilities located in St.Louis, Cleveland, Ohio and Tuttlingen, Germany. Approximately 360 employees who support this platform will transfer to STERIS upon the completion of the transaction. Annual revenue for these businesses collectively for BD’s fiscal year ended September 30, 2023, is projected to be approximately $170 million, with adjusted earnings before interest and taxes of approximately $45 million. The divestiture is expected to close within BD's fiscal year 2023 ending, September 30, 2023. Marko Zatylny and Stephanie Lapidus of Ropes and Gray, LLP were legal advisers for Becton, Dickinson and Company (NYSE:BDX). Lazard & Co., Limited is serving as financial advisor to STERIS and Anthony E. Kuhel of Thompson Hine LLP is acting as legal counsel to STERIS Corporation.Reported Earnings • May 06Second quarter 2023 earnings releasedSecond quarter 2023 results: EPS: US$1.54. Net income: US$437.0m (up US$437.0m from 2Q 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Europe.お知らせ • May 05Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the fiscal year 2023. For the year, the company expected revenues to be in the range of approximately $19.2 billion to $19.3 billion compared to $19.1 billion to $19.3 billion previously announced, which reflects an increase of approximately $50 million at the mid-point. Revenue guidance now assumes base business currency-neutral revenue growth of 6.5% to 7.0% compared to 5.75% to 6.75% previously announced, which represents an increase of 50 basis points, or approximately $90 million at the mid-point. Revenue guidance now assumes approximately $50 million in COVID-only diagnostic testing revenues, compared to approximately $50 million to $100 million previously announced. Based on current rates, foreign exchange continues to represent a reduction of approximately 200 basis points, or approximately $370 million, to total company revenue growth.お知らせ • Feb 09BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination TestBD announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons. The test, for use on the BD MAX Molecular Diagnostic System, uses a single nasal swab or a single nasopharyngeal swab sample to identify and distinguish if a patient has COVID-19, the flu, RSV or some combination of the three, with results available in as little as two hours. The test helps eliminate the need for multiple tests or doctor visits and can help clinicians implement the right treatment plan quickly. The co-testing approach also helps to increase testing capacity during the busy flu/RSV season and speed time to diagnosis. The BD MAX System is already in use at thousands of hospitals and laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period. The Respiratory Viral Panel for BD MAX System is an RT- PCR assay that detects and differentiates the nucleic acid of SARS-CoV-2, flu A, flu B and RSV in as little as two hours for the first result, with the simplified and automated workflow of the BD MAX System. Development of this combination test has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority. The BD Respiratory Viral Panel assay for BD MAX System was CE marked under the IVD directive 98/79/EC in May of 2022. It is an important addition to the extensive number of assays available on the system across respiratory infections, sexually transmitted infections, gastrointestinal infections, women's health and health care associated infections. The BD MAX open system allows customers to leverage research use only (RUO) assays and user-defined protocols (UDP) to address emerging needs quickly.お知らせ • Feb 04Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific DiscoveryBecton, Dickinson and Company announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research. The BD Rhapsody™ HT Xpress System enables scientists to isolate, barcode and analyze single cells at a high sample throughput — up to eight times more cells than prior versions of BD single-cell analyzers. The system ensures no sample loss and gives scientists the flexibility to analyze multiple samples and different cell sizes and types, such as stem cells or cancer cells, at the same time, to obtain more insights in less time. The new technology will be on display at the Advances in Genome Biology and Technology (AGBT) General Meeting February 6-9 in Hollywood, Florida. Single-cell multiomics is a rapidly growing approach that enables researchers to look at multiple layers of "omics" (including genomics, transcriptomics, proteomics and metabolomics) information on a single cell, to exponentially increase the parameters that can be investigated and uncover a more comprehensive view of health and disease. Additionally at the AGBT General Meeting, BD will introduce the BD Rhapsody™ Mouse TCR/BCR Multiomic Assay, a cell receptor profiling tool for single-cell studies, as well as BD® Flex Single-Cell Multiplexing Kits, a companion tool for single-cell studies on any BD Rhapsody system, including the BD Rhapsody™ HT Xpress System, enabling more elements to be measured in a single run by expanding the number of sample tags. BD will also present data on these latest innovations. BD is completing early-access testing for the BD Rhapsody™ HT Xpress System, which will soon be commercially available globally.Reported Earnings • Feb 04First quarter 2023 earnings released: EPS: US$1.71 (vs US$2.30 in 1Q 2022)First quarter 2023 results: EPS: US$1.71 (down from US$2.30 in 1Q 2022). Revenue: US$4.59b (down 8.2% from 1Q 2022). Net income: US$486.0m (down 26% from 1Q 2022). Profit margin: 11% (down from 13% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Europe.お知らせ • Feb 03Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023Becton, Dickinson and Company provided earnings guidance for the year 2023. For the year, the company expects fiscal year 2023 revenues to be in the range of approximately $19.1 billion to $19.3 billion compared to $18.6 billion to $18.8 billion previously announced, which reflects an increase of approximately $500 million at the mid-point.お知らせ • Jan 25BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.91 per common share, payable on March 31, 2023 to holders of record on March 10, 2023. The indicated annual dividend rate is $3.64 per share.お知らせ • Jan 12Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology LabsBecton, Dickinson and Company introduced a new, robotic track system for the BD Kiestra™ microbiology laboratory solution that automates lab specimen processing, which may help to reduce manual labor and wait time for results. The new BD Kiestra™ 3rd Generation Total Lab Automation System allows laboratories to create a custom and flexible total lab automation configuration to connect multiple BD Kiestra™ modules and is scalable to meet labs' unique and evolving needs. With multiple track options and choice of instruments to employ, labs can choose their automation entry point and configure the system to fit their individual workflow and physical lab space. From routine specimen inoculation processes to advanced incubation, imaging and colony selection for pathogen identification, the workflow can be fully automated and is customizable to fit the physical lab space. In addition, each step of the lab's diagnostic pathway is traceable and powered by BD Synapsys™ informatics solution to enable integrated workflows and on-demand insights that help empower laboratory staff to impact turnaround time, expedite laboratory decision-making, improve productivity, and support their compliance requirements.お知らせ • Jan 10Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus DetectionBecton, Dickinson and Company and CerTest Biotec have announced Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for Mpox virus detection. The VIASURE Monkeypox Virus Real Time PCR Reagents for BD MAX System is now available for BD MAX™ System users. The BD MAX™ System is a fully integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours. BD offers an extensive menu of tests on the system covering health care associated infections, respiratory infections, sexually transmitted infections, gastrointestinal infections and women's health. As with all CerTest assays, the VIASURE Monkeypox Virus PCR Detection assay for the BD MAX™ System is offered in a lyophilized format. Accordingly, the assay will come in a tube that snaps into the test-specific position on the BD MAX™ ExK™ TNA extraction strip, which is supplied by BD.お知らせ • Jan 07Becton, Dickinson and Company Announces Executive ChangesBecton, Dickinson and Company announced that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat (Sam) Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023. Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD Executive Leadership Team. Quinn joined BD in 2019 and currently serves as senior vice president, deputy general counsel, and chief ethics andcompliance officer. Before joining BD, she was vice president and general counsel of North America for Sandoz Inc. and prior to that served as vice president and associate general counsel at Catalent Pharma Solutions. Quinn holds a Juris Doctor from Villanova University and a Bachelor of Arts in Political Science from Colgate University. As part of the leadership transition, BD also announced that effective February 3, Ami Simunovich, executive vice president and chief regulatory officer, will report directly to Polen and Public Affairs will report to Simunovich. Inaddition, Corporate Development will report to Chris DelOrefice, executive vice president and chief financial officer, bringing a closer alignment between Corporate Development and Corporate Strategy. Khichi, 55, is currently general counsel and executive vice president, Corporate Development, Public Affairs andRegulatory Affairs, which he has served as since 2017, when he joined BD through the acquisition of C. R. Bard. Prior to joining BD, Khichi was senior vice president, general counsel and secretary at C. R. Bard. Prior to Bard, he served as senior vice president, chief administrative officer and general counsel for Catalent Pharma Solutions.お知らせ • Jan 06Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023Becton, Dickinson and Company announced that they will report Q1, 2023 results at 6:30 AM, US Eastern Standard Time on Feb 02, 2023お知らせ • Dec 21Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023, at 13:00 US Eastern Standard Time. Location: The Biltmore Hotel Miami Coral Gables, 1200 Anastasia Ave, Coral Gables, Florida Florida United States Agenda: To elect as directors of the eleven nominees names attached in the proxy statement doe one year term; to consider the ratification of selection of independent registered public accounting firm; to consider the advisory vote to approve named executive officer compensation; and to discuss other related matters.Buying Opportunity • Dec 03Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 28%. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings is also forecast to grow by 16% per annum over the same time period.Reported Earnings • Nov 24Full year 2022 earnings released: EPS: US$5.42 (vs US$5.23 in FY 2021)Full year 2022 results: EPS: US$5.42 (up from US$5.23 in FY 2021). Revenue: US$18.9b (down 1.4% from FY 2021). Net income: US$1.55b (up 2.0% from FY 2021). Profit margin: 8.2% (up from 7.9% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Medical Equipment industry in Europe.株主還元BOXBG Medical EquipmentBG 市場7D2.4%4.1%-0.8%1Y-14.6%-18.8%12.0%株主還元を見る業界別リターン: BOX過去 1 年間で-18.8 % の収益を上げたBG Medical Equipment業界を下回りました。リターン対市場: BOXは、過去 1 年間で12 % のリターンを上げたBG市場を下回りました。価格変動Is BOX's price volatile compared to industry and market?BOX volatilityBOX Average Weekly Movement3.1%Medical Equipment Industry Average Movement6.4%Market Average Movement4.6%10% most volatile stocks in BG Market7.5%10% least volatile stocks in BG Market2.8%安定した株価: BOX 、 BG市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: BOXの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト189773,000Tom Polenwww.bd.comベクトン・ディッキンソン アンド カンパニーは、世界中の医療機関、医師、ライフサイエンス研究者、臨床検査室、製薬業界、一般消費者向けに医療用品、機器、検査機器、診断用製品を開発、製造、販売している。同社は3つのセグメントで事業を展開している：BDメディカル、BDライフサイエンス、BDインターベンショナル。BDメディカル部門は、末梢静脈カテーテルおよび高度末梢カテーテル、中心静脈ライン、急性透析カテーテル、バスキュラーアクセス技術、血管ケアおよび準備製品、無針点滴コネクターおよびエクステンションセット、閉鎖系薬物移送装置、危険薬物検出器、皮下注射器および針、麻酔針およびトレイ、経腸用注射器、シャープス廃棄システムを提供しています；静脈内投薬の安全性と輸液療法デリバリーシステム、薬剤調合ワークフローシステム、自動薬剤分注と供給管理システム、薬剤在庫の最適化と追跡システム、プレフィラブル薬物送達システム。BDライフサイエンス部門は、検体・採血製品、自動血液・結核培養、分子検査、微生物同定・薬剤感受性、液体ベース細胞診システム、迅速診断アッセイ、微生物検査自動化製品、プレート培地製品、蛍光活性化セルソーター・アナライザー、抗体・キット、試薬システム、単一細胞遺伝子発現解析ソリューション、臨床腫瘍学・免疫学・移植診断/モニタリング試薬・アナライザーを提供しています。BDインターベンショナル部門は、ヘルニア・軟部組織修復、生物学的・生体吸収性グラフト、バイオサージェリー、その他の外科製品、外科感染予防、末梢インターベンション製品、泌尿器・クリティカルケア製品を提供している。同社は1897年に設立され、ニュージャージー州フランクリン・レイクスに本社を置いている。もっと見るBecton, Dickinson and Company 基礎のまとめBecton Dickinson の収益と売上を時価総額と比較するとどうか。BOX 基礎統計学時価総額€61.53b収益（TTM）€1.34b売上高(TTM)€18.14b46.1xPER（株価収益率3.4xP/SレシオBOX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BOX 損益計算書（TTM）収益US$19.83b売上原価US$10.93b売上総利益US$8.90bその他の費用US$7.44b収益US$1.46b直近の収益報告Jun 30, 2024次回決算日Nov 07, 2024一株当たり利益（EPS）5.05グロス・マージン44.90%純利益率7.36%有利子負債／自己資本比率74.7%BOX の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.6%現在の配当利回り75%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/08 15:24終値2024/08/08 00:00収益2024/06/30年間収益2023/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Becton, Dickinson and Company 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30 アナリスト機関David ToungArgus Research CompanyAdam FeinsteinBarclaysMatthew MiksicBarclays27 その他のアナリストを表示
Reported Earnings • Aug 02Third quarter 2024 earnings released: EPS: US$1.68 (vs US$1.37 in 3Q 2023)Third quarter 2024 results: EPS: US$1.68 (up from US$1.37 in 3Q 2023). Revenue: US$4.99b (up 2.3% from 3Q 2023). Net income: US$487.0m (up 24% from 3Q 2023). Profit margin: 9.8% (up from 8.0% in 3Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Europe.
お知らせ • Aug 01Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024Becton, Dickinson and Company updated earnings guidance for the year 2024. For the year, the company expects GAAP Revenues in the range of $20.1 billion compared to the previous guidance of $20.1 to $20.3 billion provided earlier and expects GAAP Revenue Growth of 3.7%. Organic Revenue Growth of 5.0% to 5.25% compared to the previous guidance of 5.5% to 6.25% provided earlier.
お知らせ • Jul 24Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024The Board of Directors of BD (Becton, Dickinson and Company) announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share.
お知らせ • Jul 04Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024Becton, Dickinson and Company announced that they will report Q3, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 01, 2024
お知らせ • Jun 26BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research ToolBD (Becton, Dickinson and Company) announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases. Researchers worldwide are currently using innovative approaches to study multiple aspects of health and disease at a single-cell level. In the ever-evolving field of biological research, the newly launched BD Rhapsody Single Cell ATAC-Seq (assay for transposase-accessible chromatin using next-generation sequencing) Assay enables scientists to perform single-cell analysis of the epigenome – the set of chemical marks, or epigenetic changes, on the DNA in a single cell that holds critical clues about mechanisms of disease. Adding an epigenomic layer-view will play a crucial role in helping researchers track and understand how environmental factors impact the DNA and corresponding cell function. By gaining such knowledge about DNA, scientists can deepen their understanding of how diseases progress and apply those learnings to develop effective therapies. Commercially available globally June 26, 2024, the BD Rhapsody ATAC-Seq Assay, BD Rhapsody TCR/BCR Next Multiomic Assay and BD Rhapsody Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell research. The BD single-cell multiomics portfolio is available for purchase from BD representatives, or in some regions, through its ecommerce portal.
お知らせ • Jun 05Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion on June 3, 2024. BD expects to fund the all-cash transaction with approximately $1 billion of cash and $3.2 billion of new debt. Upon closing, Critical Care will operate as a separate business unit within BD’s Medical segment to align with its smart connected care approach, and it will maintain its presence in Irvine, Calif. Katie Szyman, who has served as corporate vice president of Critical Care since 2015, will lead the new business unit within BD, reporting to Mike Garrison, executive vice president and president of the BD Medical segment. The transaction is subject to customary regulatory reviews, the receipt of required antitrust and foreign investment approvals and closing conditions. The transaction is expected to close before the end of the 2024. At closing, BD is expected to have net leverage of approximately 3x and expects to de-lever to its 2.5x long-term net leverage target within 12 to 18 months of closing, primarily by deploying its free cash flows to debt repayment. The transaction meets all of BD’s rigorous investment criteria on growth, profitability and returns. It is expected to be immediately accretive to all key financial measures, including BD’s revenue growth, adjusted gross and operating margins, and adjusted earnings per share. Critical Care’s long-term financial profile is also expected to deliver durable revenue growth of approximately 6% to 7%, with year-one adjusted gross margin of at least 60% and adjusted operating margins of at least 25% that increase over time. Consistent with the company’s BD 2025 strategy, growth-enhancing and value-creating tuck-in M&A continues to be a key part of BD’s targeted financial profile. Perella Weinberg Partners and Citi acted as financial advisers, and Ropes & Gray, LLP acted as legal counsel to BD. Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC acted as financial advisors, and Skadden Arps acted as legal counsel to Edwards.
Reported Earnings • Aug 02Third quarter 2024 earnings released: EPS: US$1.68 (vs US$1.37 in 3Q 2023)Third quarter 2024 results: EPS: US$1.68 (up from US$1.37 in 3Q 2023). Revenue: US$4.99b (up 2.3% from 3Q 2023). Net income: US$487.0m (up 24% from 3Q 2023). Profit margin: 9.8% (up from 8.0% in 3Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Europe.
お知らせ • Aug 01Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024Becton, Dickinson and Company updated earnings guidance for the year 2024. For the year, the company expects GAAP Revenues in the range of $20.1 billion compared to the previous guidance of $20.1 to $20.3 billion provided earlier and expects GAAP Revenue Growth of 3.7%. Organic Revenue Growth of 5.0% to 5.25% compared to the previous guidance of 5.5% to 6.25% provided earlier.
お知らせ • Jul 24Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024The Board of Directors of BD (Becton, Dickinson and Company) announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share.
お知らせ • Jul 04Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024Becton, Dickinson and Company announced that they will report Q3, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 01, 2024
お知らせ • Jun 26BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research ToolBD (Becton, Dickinson and Company) announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases. Researchers worldwide are currently using innovative approaches to study multiple aspects of health and disease at a single-cell level. In the ever-evolving field of biological research, the newly launched BD Rhapsody Single Cell ATAC-Seq (assay for transposase-accessible chromatin using next-generation sequencing) Assay enables scientists to perform single-cell analysis of the epigenome – the set of chemical marks, or epigenetic changes, on the DNA in a single cell that holds critical clues about mechanisms of disease. Adding an epigenomic layer-view will play a crucial role in helping researchers track and understand how environmental factors impact the DNA and corresponding cell function. By gaining such knowledge about DNA, scientists can deepen their understanding of how diseases progress and apply those learnings to develop effective therapies. Commercially available globally June 26, 2024, the BD Rhapsody ATAC-Seq Assay, BD Rhapsody TCR/BCR Next Multiomic Assay and BD Rhapsody Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell research. The BD single-cell multiomics portfolio is available for purchase from BD representatives, or in some regions, through its ecommerce portal.
お知らせ • Jun 05Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion on June 3, 2024. BD expects to fund the all-cash transaction with approximately $1 billion of cash and $3.2 billion of new debt. Upon closing, Critical Care will operate as a separate business unit within BD’s Medical segment to align with its smart connected care approach, and it will maintain its presence in Irvine, Calif. Katie Szyman, who has served as corporate vice president of Critical Care since 2015, will lead the new business unit within BD, reporting to Mike Garrison, executive vice president and president of the BD Medical segment. The transaction is subject to customary regulatory reviews, the receipt of required antitrust and foreign investment approvals and closing conditions. The transaction is expected to close before the end of the 2024. At closing, BD is expected to have net leverage of approximately 3x and expects to de-lever to its 2.5x long-term net leverage target within 12 to 18 months of closing, primarily by deploying its free cash flows to debt repayment. The transaction meets all of BD’s rigorous investment criteria on growth, profitability and returns. It is expected to be immediately accretive to all key financial measures, including BD’s revenue growth, adjusted gross and operating margins, and adjusted earnings per share. Critical Care’s long-term financial profile is also expected to deliver durable revenue growth of approximately 6% to 7%, with year-one adjusted gross margin of at least 60% and adjusted operating margins of at least 25% that increase over time. Consistent with the company’s BD 2025 strategy, growth-enhancing and value-creating tuck-in M&A continues to be a key part of BD’s targeted financial profile. Perella Weinberg Partners and Citi acted as financial advisers, and Ropes & Gray, LLP acted as legal counsel to BD. Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC acted as financial advisors, and Skadden Arps acted as legal counsel to Edwards.
お知らせ • May 03Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024Becton, Dickinson and Company revised earnings guidance for the fiscal year 2024. For the year, company expects revenues to be in the range of approximately $20.1 billion to $20.3 billion compared to previous guidance of $20.2 billion to $20.4 billion. The company now expects organic revenue growth to be 5.5% to 6.25% compared to previous guidance of 5.5% to 6.25%.
Reported Earnings • May 02Second quarter 2024 earnings released: EPS: US$1.86 (vs US$1.54 in 2Q 2023)Second quarter 2024 results: EPS: US$1.86 (up from US$1.54 in 2Q 2023). Revenue: US$5.05b (up 4.6% from 2Q 2023). Net income: US$537.0m (up 23% from 2Q 2023). Profit margin: 11% (up from 9.1% in 2Q 2023). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe.
お知らせ • May 01Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024The Board of Directors of BD (Becton, Dickinson and Company) announced it has declared a quarterly dividend of $0.95 per common share, payable on June 28, 2024 to holders of record on June 10, 2024. The indicated annual dividend rate is $3.80 per share.
お知らせ • Apr 27Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC recently.
お知らせ • Apr 05+ 1 more updateBecton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024Becton, Dickinson and Company announced that they will report Q2, 2024 results at 6:30 AM, US Eastern Standard Time on May 02, 2024
お知らせ • Mar 06Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial DiseaseBecton, Dickinson and Company announced the enrollment of the first patient in the investigational device exemption (IDE) study, AGILITY, which will assess the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Peripheral Arterial Disease (PAD). The investigational Vascular Covered Stent is a self-expanding, low profile, polytetrafluoroethylene encapsulated nitinol implant. It is deployed from a delivery system that provides controlled stent release. According to BD, the global, prospective, multi-center, single-arm, non-randomized AGILITY clinical study will include 315 patients at up to 40 clinical study sites across the United States, Europe, Australia and New Zealand. Follow-up for all treated patients will be performed at various points after treatment starting at one month and ending at 36 months. PAD affects more than 18 million Americans and more than 236 million people worldwide. It is a potentially debilitating disease that can lead to increased risk of cardiovascular complications and limb amputation. A healthy diet, exercise and cessation of smoking can help mitigate the development of PAD, which includes the formation of atherosclerosis and blood clots in arteries in the legs. Minimally invasive techniques using devices such as angioplasty balloons, drug-coated balloons, atherectomy and covered stents can be used to increase blood flow through the diseased areas. The first patient in the AGILITY study was enrolled at Trinity Medical Center in Bettendorf, Iowa by Dr. Nicolas Shammas, Interventional Cardiologist, Cardiovascular Medicine, PLLC.
お知らせ • Feb 29Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024BD (Becton, Dickinson and Company) announced that Dave Hickey has informed the company of his intent to retire from BD, effective July 1, 2024. Hickey is currently executive vice president and president of the Life Sciences segment for BD, a position he has held since January 2021. Prior to his current role, Hickey was president of Integrated Diagnostic Solutions from 2019 to 2021, and president of Diagnostic Systems prior to that. Before joining BD in 2014, Hickey served in a range of executive leadership positions at Siemens Healthcare. BD intends to name a successor to Hickey prior to his retirement date.
Reported Earnings • Feb 01First quarter 2024 earnings released: EPS: US$0.97 (vs US$1.71 in 1Q 2023)First quarter 2024 results: EPS: US$0.97 (down from US$1.71 in 1Q 2023). Revenue: US$4.71b (up 2.6% from 1Q 2023). Net income: US$281.0m (down 42% from 1Q 2023). Profit margin: 6.0% (down from 11% in 1Q 2023). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Europe.
お知らせ • Feb 01Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024Becton, Dickinson and Company raised earnings guidance for the fiscal year of 2024. For the year, company expects revenues to be in the range of approximately $20.2 billion to $20.4 billion compared to $20.1 billion to $20.3 billion previously and Organic revenue growth is now expected to be 5.5% to 6.25% compared to 5.25% to 6.25% previously.
お知らせ • Jan 24Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024The Board of Directors of Becton, Dickinson and Company announced it has declared a quarterly dividend of $0.95 per common share, payable on March 29, 2024 to holders of record on March 8, 2024. The indicated annual dividend rate is $3.80 per share.
お知らせ • Jan 05Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024Becton, Dickinson and Company announced that they will report Q1, 2024 results at 6:30 AM, US Eastern Standard Time on Feb 01, 2024
お知らせ • Dec 16Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024, at 13:00 US Eastern Standard Time.
お知らせ • Dec 08BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection DeviceBD announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests. The BD MiniDraw™ Capillary Blood Collection System is less invasive than a traditional venous blood draw by using capillary blood collected from a patient's finger by a trained healthcare worker, without the need for a phlebotomist to collect blood from a vein. The innovative design provides a sample that produces lab-quality blood test results from a fraction of the volume of traditional venous collections. It is less invasive than traditional venous blood collection methods and more convenient for the patient by expanding access to blood collection to new locations, including retail pharmacies. The device may provide a better patient experience and has the potential to transform diagnostic testing. The 510(k) clearances include low-volume blood collection for a lipid panel, selected chemistry tests, and hemoglobin and hematocrit (H&H) testing. These tests are among the most commonly ordered lab tests and can be used to diagnose and monitor a variety of chronic conditions from hypertension to high cholesterol. BD plans to expand blood tests enabled by BD MiniDraw™ Collection System in the future.Traditionally when a patient requires "blood work," a doctor orders the test, and an appointment is made at a laboratory service center where a nurse or phlebotomist draws tubes of blood from the patient's vein. The BD MiniDraw™ Collection System has the potential to transform this experience by expanding blood testing to new, more convenient settings, which can benefit patients, health care providers and collection sites. For patients, capillary collection with the BD MiniDraw™ Collection System provides the convenience of having blood drawn somewhere they already frequent, like a retail pharmacy or grocery store, which may have longer hours of operation and be closer to where they live or work. For these non-traditional collection sites, it enables expansion beyond existing health and wellness programs like administering vaccinations and can generate additional store traffic. For health care providers, capillary blood collection could be offered at a physician's office without the need for a phlebotomist. Making blood collection easier and less invasive may improve patient adherence to blood testing, for example, as part of annual wellness checks, which could lead to earlier diagnosis and better monitoring of chronic conditions. In May 2022, BD and Babson Diagnostics announced an expansion of their original strategic partnership agreement, announced in 2020, to advance development of the Babson BetterWay™ blood testing ecosystem, which includes the BD MiniDraw™ Collection System and Babson's proprietary automated sample-handling and analytical technologies. These were designed to work together to enable blood testing that requires only a fraction of the sample volume of traditional venipuncture methods without sacrificing quality or accuracy.
お知らせ • Nov 30BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician EfficiencyBD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices. The SiteRite™? 9 Ultrasound System is an all-in-one system designed with a user-friendly experience on an updated 15.6-inch touch screen with enhanced image quality that provides catheter placement tools and technologies to support clinicians during the vascular access device insertion process. The system includes integrated visualization tools such as the Cue™? Needle Tracking System to provide nurses with continuous and real-time needle tracking, and the Sherlock 3CG+™? Tip Confirmation System to ensure proper catheter tip navigation and location. SiteRite™? 9 also features smart, connected technology such as vessel assessment tools that automatically detect the vessel, then pair with vessel measurement tools to help clinicians select the appropriate catheter, so they can make an informed decision every time. Additional system capabilities include patient data look up with information capture, auto-filling capabilities and records transfer to help support clinician workflow.
お知らせ • Nov 23Becton, Dickinson and Company Announces Executive ChangesBecton, Dickinson and Company (BDX) named Ronald Silverman as executive vice president and chief medical officer, effective Dec. 4, 2023. Silverman succeeds William Sigmund, who had announced his wish to retire in June this year. Silverman was chief medical officer at 3M Health Care before joining BD.
New Risk • Nov 14New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 30% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results.
Reported Earnings • Nov 14Full year 2023 earnings released: EPS: US$5.14 (vs US$5.42 in FY 2022)Full year 2023 results: EPS: US$5.14 (down from US$5.42 in FY 2022). Revenue: US$19.4b (up 2.7% from FY 2022). Net income: US$1.47b (down 4.9% from FY 2022). Profit margin: 7.6% (down from 8.2% in FY 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Europe.
お知らせ • Nov 12Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023The Board of Directors of Becton, Dickinson and Company has declared a quarterly dividend of $0.95 per common share, an increase of 4.4% from the previous quarter. The dividend will be payable on December 29, 2023 to holders of record on December 8, 2023. The indicated annual dividend rate for fiscal year 2024 is $3.80 per share.
お知らせ • Nov 10Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024Becton, Dickinson and Company provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of approximately $20.1 billion to $20.3 billion. Organic revenue growth is expected to be 5.25% to 6.25% including a headwind of over 25 basis points from the expected decline in COVID-only diagnostic testing. Total currency-neutral revenue growth is expected to be 4.5% to 5.5%. The company expects fiscal year 2024 adjusted diluted EPS to be $12.70 to $13.00, which represents growth of approximately 4% to 6.5%.
Buying Opportunity • Nov 09Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 19%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.
お知らせ • Nov 03Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw TechnologyBecton, Dickinson and Company launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company's vision of a "One-Stick Hospital Stay." With 510(k) clearance from the U.S. Food and Drug Administration (FDA), the new PIVO Pro Needle-free Blood Collection Device features design improvements to achieve the first and only compatibility with integrated and long peripheral IV catheters, including the new Nexiva Closed IV Catheter System with NearPort IV Access. This expands on current PIVO compatibility with traditional short peripheral IV catheters available since 2017. The new solution combines the clinical benefits shown for the integrated closed Nexiva Catheter System, including longer dwell times and reduced catheter complications, with the ability to draw high-quality blood samples directly from a patient's peripheral IV line with PIVO Pro, reducing the need for additional needlesticks. With needle phobia experienced by more than 60 percent of the adult population, this solution helps improve the patient experience by alleviating fear and anxiety associated with repetitive needlesticks. This new solution helps to reduce unnecessary and repeat needlesticks in the hospital while elevating clinical outcomes, improving workflow and creating a better experience for clinicians and patients." Peripheral IV insertion and blood collection are two of the most common in-patient procedures in hospitals touching almost every patient daily. These invasive procedures are associated with a variety of complications such as poor first-stick insertion success, frequent catheter failures and poor sample quality that can extend hospital stays, increase cost and create a dissatisfying experience. PIVO Pro combined with Nexiva with NearPort IV Access is designed to access optimal blood draw conditions and help improve clinician efficiency and patient experience. The innovative line draw solution has been shown to help optimize IV performance, reduce sample errors that can result in redraws and delays in patient care while reducing complications that lead to unnecessary procedures and IV replacements. By removing the needle from blood draws and reducing IV replacements, it may reduce the risk of needlestick injury and blood exposure for clinicians while preserving a patient's vessel health.(7,9,10) As the global leader in vascular access solutions, BD is committed to advancing the standard of care for IV therapy and blood draws for patients and health care providers. The latest innovation in the BD Peripheral Line Draw Solution further drives the BD "One-Stick Hospital Stay" vision across each of its three pillars _ including (1) helping to reduce unnecessary needlesticks by choosing the right vascular access device and placing it successfully the first time; (2) using one IV line as a single access point for required therapies and blood draws; and (3) optimal maintenance of the IV line to help reduce the risk of complications so it does not have to be replaced and lasts throughout a patient's hospital stay. Compared to open catheter system- Clinical studies were done on previous generations of the PIVO Blood Collection Device and Nexiva Catheter System. PIVO Pro and Nexiva with NearPort IV Access are the next generations of their respective product families.
お知らせ • Oct 18BD Names Greg Rodetis as Senior Vice President of Investor RelationsBD (Becton, Dickinson and Company) announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately. In this expanded role, Greg will continue as company treasurer and also lead all aspects of communicating progress of BD's strategy to investors and the financial community, including the company's initiatives that drive shareholder value. Rodetis will continue to report to Chris DelOrefice, executive vice president and chief financial officer for BD. Rodetis joined BD in 2016 as vice president and assistant treasurer, capital markets. In his current role as treasurer, Rodetis is responsible for leadership and oversight of the company's Treasury function as a strategic partner in supporting business performance, earnings growth and shareholder return. Prior to BD, Greg was with Terex Corporation as the assistant treasurer and prior to this he held roles of progressive responsibility with PepsiCo Inc., and General Electric Company. Rodetis holds a Bachelor of Science in Finance from Boston College and is a CFA® Charterholder.
お知らせ • Oct 13Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023Becton, Dickinson and Company announced that they will report Q4, 2023 results at 6:30 AM, US Eastern Standard Time on Nov 09, 2023
Buying Opportunity • Sep 29Now 21% undervaluedOver the last 90 days, the stock is up 1.7%. The fair value is estimated to be €309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 19%. For the next 3 years, revenue is forecast to grow by 5.0% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.
New Risk • Aug 04New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results.
お知らせ • Aug 04+ 1 more updateBecton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the full fiscal year 2023. For the period, Company now expects revenues to be approximately $19.3 billion compared to $19.2 billion to $19.3 billion previously announced. Revenue guidance now assumes base business currency-neutral revenue growth of 6.8% to 7.1% before the impact of the Surgical Instrumentation platform divestiture. This reflects an increase of 25 basis points at the mid-point to 7.0%, driven by strong third quarter performance. Base organic revenue growth is now expected to be 5.5% to 5.8%, compared to 5.25% to 5.75% previously announced, and continues to reflect fourth quarter organic revenue growth of about 6%.
Reported Earnings • Aug 03Third quarter 2023 earnings released: EPS: US$1.37 (vs US$1.29 in 3Q 2022)Third quarter 2023 results: EPS: US$1.37 (up from US$1.29 in 3Q 2022). Revenue: US$4.88b (up 5.1% from 3Q 2022). Net income: US$392.0m (up 6.8% from 3Q 2022). Profit margin: 8.0% (up from 7.9% in 3Q 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Europe.
お知らせ • Jul 25Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the BoardOn July 24, 2023, Dr. Joanne Waldstreicher was elected to the Board of Directors of Becton, Dickinson and Company (BD"). Upon joining BD's Board of Directors, Dr. Waldstreicher will serve as a member of both the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board. BD's Board of Directors has determined that Dr. Waldstreicher is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD's Statement of Corporate Governance Principles. Information regarding the compensation of the non-management members of BD's Board of Directors is included under the caption Non-Management Director Compensation" in BD's proxy statement relating to its 2023 Annual Meeting of Shareholders.
お知らせ • Jul 23Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion SystemBD (Becton, Dickinson and Company) announced that the updated BD Alaris Infusion System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the United States. This clearance covers updated hardware features for Point-of-Care Unit (PCU), large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring and auto-identification modules. It also covers a new BD Alaris Infusion System software version with enhanced cybersecurity, along with interoperability features that enable smart, connected care with the most widely used electronic medical record (EMR) systems. Extending BD's Decades-Long Legacy of Leadership in Infusion Innovation: Today's clearance further enhances BD leadership in the infusion pump market. The updated BD Alaris Infusion system will help empower hospitals and health systems to optimize their workflows and deliver a higher standard of care, which has never been more important than in today's health care environment of staffing shortages and resource constraints. The BD Alaris Infusion System is the only system with a centralized user interface for up to four modules for all major types of infusions, including large volume pumps, syringe pump, and PCA therapy with optional respiratory monitoring. Having one, comprehensive infusion system enables hospitals and health systems to easily scale their infusion needs across an entire integrated delivery network and provide interoperability with EMR interoperability. With a common Point-of-Care Unit, one interface controls all modules, which is different from other pumps on the market that have non-modular architecture. The "one system" approach offers ease, simplicity and scalability. The BD Alaris infusion System also has the breadth of customers, the number of nurses trained on its use and the broadest experience and number of customers with EMR interoperability. Without this type of digital connectivity, clinicians are often required to navigate time-consuming processes, taking multiple steps to manually program infusions. The BD Alaris Inf Fusion System can also feed data to the BD HealthSight™? platform for enterprise medication management, which is a unique combination of connective technologies, analytics and expert services that turn information into insights among caregivers and create seamless visibility across BD medication management solutions. With this platform, health systems can view infusion status in real-time as well as access an intuitive knowledge portal with actionable information related to clinician trends and drug and fluid libraries.
お知らせ • Jul 07Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023Becton, Dickinson and Company announced that they will report Q3, 2023 results at 9:30 AM, US Eastern Standard Time on Aug 03, 2023
お知らせ • Jun 21STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.STERIS Corporation entered into an agreement to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million On June 15, 2023. The purchase price is subject to customary adjustments. STERIS Corporation will acquire the BD platform assets relating to surgical instrumentation, laparoscopic instrumentation and sterilization containers, including the V. Mueller, Snowden Pencer and Genesis branded products. The purchase price for the Transaction is $540 million in cash, subject to customary adjustments. STERIS is not assuming any debt and intends to fund the Transaction through a combination of debt and cash on hand. STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill, with a present value of approximately $60 million. The Purchase Agreement also imposes customary confidentiality, non-solicitation and non-compete obligations upon the BD. The Purchase Agreement provides STERIS and the BD with certain termination rights. The completion of the Transaction is subject to the satisfaction or waiver of a number of customary conditions, including receipt of requisite Hart-Scott-Rodino Act approvals and Federal Trade Commission (FTC) regulatory approval. The divestiture will include V. Mueller™, Snowden-Pencer™ and Genesis™ branded products and three manufacturing facilities located in St.Louis, Cleveland, Ohio and Tuttlingen, Germany. Approximately 360 employees who support this platform will transfer to STERIS upon the completion of the transaction. Annual revenue for these businesses collectively for BD’s fiscal year ended September 30, 2023, is projected to be approximately $170 million, with adjusted earnings before interest and taxes of approximately $45 million. The divestiture is expected to close within BD's fiscal year 2023 ending, September 30, 2023. Marko Zatylny and Stephanie Lapidus of Ropes and Gray, LLP were legal advisers for Becton, Dickinson and Company (NYSE:BDX). Lazard & Co., Limited is serving as financial advisor to STERIS and Anthony E. Kuhel of Thompson Hine LLP is acting as legal counsel to STERIS Corporation.
Reported Earnings • May 06Second quarter 2023 earnings releasedSecond quarter 2023 results: EPS: US$1.54. Net income: US$437.0m (up US$437.0m from 2Q 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Europe.
お知らせ • May 05Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the fiscal year 2023. For the year, the company expected revenues to be in the range of approximately $19.2 billion to $19.3 billion compared to $19.1 billion to $19.3 billion previously announced, which reflects an increase of approximately $50 million at the mid-point. Revenue guidance now assumes base business currency-neutral revenue growth of 6.5% to 7.0% compared to 5.75% to 6.75% previously announced, which represents an increase of 50 basis points, or approximately $90 million at the mid-point. Revenue guidance now assumes approximately $50 million in COVID-only diagnostic testing revenues, compared to approximately $50 million to $100 million previously announced. Based on current rates, foreign exchange continues to represent a reduction of approximately 200 basis points, or approximately $370 million, to total company revenue growth.
お知らせ • Feb 09BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination TestBD announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons. The test, for use on the BD MAX Molecular Diagnostic System, uses a single nasal swab or a single nasopharyngeal swab sample to identify and distinguish if a patient has COVID-19, the flu, RSV or some combination of the three, with results available in as little as two hours. The test helps eliminate the need for multiple tests or doctor visits and can help clinicians implement the right treatment plan quickly. The co-testing approach also helps to increase testing capacity during the busy flu/RSV season and speed time to diagnosis. The BD MAX System is already in use at thousands of hospitals and laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period. The Respiratory Viral Panel for BD MAX System is an RT- PCR assay that detects and differentiates the nucleic acid of SARS-CoV-2, flu A, flu B and RSV in as little as two hours for the first result, with the simplified and automated workflow of the BD MAX System. Development of this combination test has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority. The BD Respiratory Viral Panel assay for BD MAX System was CE marked under the IVD directive 98/79/EC in May of 2022. It is an important addition to the extensive number of assays available on the system across respiratory infections, sexually transmitted infections, gastrointestinal infections, women's health and health care associated infections. The BD MAX open system allows customers to leverage research use only (RUO) assays and user-defined protocols (UDP) to address emerging needs quickly.
お知らせ • Feb 04Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific DiscoveryBecton, Dickinson and Company announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research. The BD Rhapsody™ HT Xpress System enables scientists to isolate, barcode and analyze single cells at a high sample throughput — up to eight times more cells than prior versions of BD single-cell analyzers. The system ensures no sample loss and gives scientists the flexibility to analyze multiple samples and different cell sizes and types, such as stem cells or cancer cells, at the same time, to obtain more insights in less time. The new technology will be on display at the Advances in Genome Biology and Technology (AGBT) General Meeting February 6-9 in Hollywood, Florida. Single-cell multiomics is a rapidly growing approach that enables researchers to look at multiple layers of "omics" (including genomics, transcriptomics, proteomics and metabolomics) information on a single cell, to exponentially increase the parameters that can be investigated and uncover a more comprehensive view of health and disease. Additionally at the AGBT General Meeting, BD will introduce the BD Rhapsody™ Mouse TCR/BCR Multiomic Assay, a cell receptor profiling tool for single-cell studies, as well as BD® Flex Single-Cell Multiplexing Kits, a companion tool for single-cell studies on any BD Rhapsody system, including the BD Rhapsody™ HT Xpress System, enabling more elements to be measured in a single run by expanding the number of sample tags. BD will also present data on these latest innovations. BD is completing early-access testing for the BD Rhapsody™ HT Xpress System, which will soon be commercially available globally.
Reported Earnings • Feb 04First quarter 2023 earnings released: EPS: US$1.71 (vs US$2.30 in 1Q 2022)First quarter 2023 results: EPS: US$1.71 (down from US$2.30 in 1Q 2022). Revenue: US$4.59b (down 8.2% from 1Q 2022). Net income: US$486.0m (down 26% from 1Q 2022). Profit margin: 11% (down from 13% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Europe.
お知らせ • Feb 03Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023Becton, Dickinson and Company provided earnings guidance for the year 2023. For the year, the company expects fiscal year 2023 revenues to be in the range of approximately $19.1 billion to $19.3 billion compared to $18.6 billion to $18.8 billion previously announced, which reflects an increase of approximately $500 million at the mid-point.
お知らせ • Jan 25BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.91 per common share, payable on March 31, 2023 to holders of record on March 10, 2023. The indicated annual dividend rate is $3.64 per share.
お知らせ • Jan 12Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology LabsBecton, Dickinson and Company introduced a new, robotic track system for the BD Kiestra™ microbiology laboratory solution that automates lab specimen processing, which may help to reduce manual labor and wait time for results. The new BD Kiestra™ 3rd Generation Total Lab Automation System allows laboratories to create a custom and flexible total lab automation configuration to connect multiple BD Kiestra™ modules and is scalable to meet labs' unique and evolving needs. With multiple track options and choice of instruments to employ, labs can choose their automation entry point and configure the system to fit their individual workflow and physical lab space. From routine specimen inoculation processes to advanced incubation, imaging and colony selection for pathogen identification, the workflow can be fully automated and is customizable to fit the physical lab space. In addition, each step of the lab's diagnostic pathway is traceable and powered by BD Synapsys™ informatics solution to enable integrated workflows and on-demand insights that help empower laboratory staff to impact turnaround time, expedite laboratory decision-making, improve productivity, and support their compliance requirements.
お知らせ • Jan 10Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus DetectionBecton, Dickinson and Company and CerTest Biotec have announced Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for Mpox virus detection. The VIASURE Monkeypox Virus Real Time PCR Reagents for BD MAX System is now available for BD MAX™ System users. The BD MAX™ System is a fully integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours. BD offers an extensive menu of tests on the system covering health care associated infections, respiratory infections, sexually transmitted infections, gastrointestinal infections and women's health. As with all CerTest assays, the VIASURE Monkeypox Virus PCR Detection assay for the BD MAX™ System is offered in a lyophilized format. Accordingly, the assay will come in a tube that snaps into the test-specific position on the BD MAX™ ExK™ TNA extraction strip, which is supplied by BD.
お知らせ • Jan 07Becton, Dickinson and Company Announces Executive ChangesBecton, Dickinson and Company announced that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat (Sam) Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023. Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD Executive Leadership Team. Quinn joined BD in 2019 and currently serves as senior vice president, deputy general counsel, and chief ethics andcompliance officer. Before joining BD, she was vice president and general counsel of North America for Sandoz Inc. and prior to that served as vice president and associate general counsel at Catalent Pharma Solutions. Quinn holds a Juris Doctor from Villanova University and a Bachelor of Arts in Political Science from Colgate University. As part of the leadership transition, BD also announced that effective February 3, Ami Simunovich, executive vice president and chief regulatory officer, will report directly to Polen and Public Affairs will report to Simunovich. Inaddition, Corporate Development will report to Chris DelOrefice, executive vice president and chief financial officer, bringing a closer alignment between Corporate Development and Corporate Strategy. Khichi, 55, is currently general counsel and executive vice president, Corporate Development, Public Affairs andRegulatory Affairs, which he has served as since 2017, when he joined BD through the acquisition of C. R. Bard. Prior to joining BD, Khichi was senior vice president, general counsel and secretary at C. R. Bard. Prior to Bard, he served as senior vice president, chief administrative officer and general counsel for Catalent Pharma Solutions.
お知らせ • Jan 06Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023Becton, Dickinson and Company announced that they will report Q1, 2023 results at 6:30 AM, US Eastern Standard Time on Feb 02, 2023
お知らせ • Dec 21Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023, at 13:00 US Eastern Standard Time. Location: The Biltmore Hotel Miami Coral Gables, 1200 Anastasia Ave, Coral Gables, Florida Florida United States Agenda: To elect as directors of the eleven nominees names attached in the proxy statement doe one year term; to consider the ratification of selection of independent registered public accounting firm; to consider the advisory vote to approve named executive officer compensation; and to discuss other related matters.
Buying Opportunity • Dec 03Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 28%. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings is also forecast to grow by 16% per annum over the same time period.
Reported Earnings • Nov 24Full year 2022 earnings released: EPS: US$5.42 (vs US$5.23 in FY 2021)Full year 2022 results: EPS: US$5.42 (up from US$5.23 in FY 2021). Revenue: US$18.9b (down 1.4% from FY 2021). Net income: US$1.55b (up 2.0% from FY 2021). Profit margin: 8.2% (up from 7.9% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Medical Equipment industry in Europe.
